Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase, expressed in 50% of non-small cell lung cancer(NSCLC), which is closely related to the occurrence and development of tumors. EGFR gene mutation is the most important predictor of the efficacyof EGFR kinase inhibitors (TKI) and is a prerequisite for clinically determining whether patients can use EGFR-TKI therapy. Boththe National Comprehensive Cancer Network (NCCN) and the Chinese Society of Clinical Oncology (CSCO) guidelinesinclude EGFR mutation detection as a category 1 recommendation.

Clinical Significance
1. The detection of EGFR mutation for stage II/III non-squamous cell carcinoma after operation can help guide adjuvating
targeted therapies.
2. The detection of EGFR mutation for inoperable stage III and IV NSCLC patients, can help guide the treatmentsaccording
to molecular classification.
3. For patients with EGFR-TKI resistance, it is recommended to perform another biopsy for EGFR gene mutation detection.

To visit website, click here